Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations

Moreno-Pérez, David; García, Francisco José Álvarez; Aldeán, Javier Álvarez; Ortega, María José Cilleruelo; Sánchez, María Garcés; Sánchez, Nuria García; Merino, Ángel Hernández; Hernández, M.; Moína, M. Merino; Melián, Abián Montesdeoca; Ruiz–Contreras, Jesús

doi:10.1016/j.anpede.2018.11.001

Cited by 7 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cases with one or more doses of different vaccine types have been included in the vaccine group with the highest number of serotypes. During this period, PCV13 vaccination in Catalonia followed the recommendations of the Spanish Association of Pediatrics . Vaccine failure was defined according to the Council for the International Organizations of Medical Sciences and the World Health Organization Working Group as IPD produced by PCV13 serotypes in a correctly vaccinated subject …”

Section: Methodsmentioning

confidence: 99%

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Díaz-Conradi

Hernández

García‐García

et al. 2019

Pediatric Pulmonology

View full text Add to dashboard Cite

Aim: The aim was to analyze the epidemiological, microbiological and clinical characteristics of patients with complicated pneumococcal pneumonia with pleural effusion (PE) or empyema. Method: Prospective study in three Catalan hospitals in persons aged <18 years diagnosed with complicated pneumonia with PE or empyema with isolation of Streptococcus pneumoniae in blood or pleural fluid by culture or real-time PCR between January 2012 and June 2016. Patients were divided into <2 years and 2-17 years age groups. Epidemiological, microbiological, and clinical data of patients were compared annually in both groups. PCV13 vaccination coverage increased from 48.2% in 2012 to 74.5% in 2015. Results:We included 143 patients. The incidence of pneumococcal pneumonia was 6.83 cases × 10 −5 persons/year in cases with PE or empyema and 2.09 cases × 10 −5 person-years in cases without (rate ratio [RR]: 3.27; 2.25-4.86; P < 0.001). Empyema was more frequent than PE (79.7% vs 20.3%, P < 0.005). Of 143 cases studied, 93 (65.0%, P < 0.001) were diagnosed by real-time-PCR, 43 (30.1%) by culture and RT-PCR and 7 (4.9%) by culture only. PCV13 serotypes were more frequent in complicated than in uncomplicated pneumonia (116/142, 81.7% vs 27/45, 60.0%; P = 0.003), especially serotype 1 (41/142, 28.9% vs 6/45, 13.3%, P : 0.036). From 2012 to 2015 there was a significant reduction in serotype 1 (16/43, 37.2% vs 3/27, 11.1%, P = 0.026), and a trend to an increase in non-PCV13 serotypes (6/43, 14% vs 9/27, 33.3%, P = 0.054). Conclusions:A directly proportional relationship was observed between the reduction in pneumonia complicated with PE or empyema and a significant

show abstract

Section: Methodsmentioning

confidence: 99%

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Díaz-Conradi

Hernández

García‐García

et al. 2019

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…In recent years, meningococcal serogroup W (MenW) has been an increasing cause of disease across all age groups and in many geographically dispersed countries [69,76,77]. As a direct consequence quadrivalent ACWY vaccines have been added as a single adolescent dose to induce herd protection into the immunization programs of countries including the UK (2015), Ireland (2016), the Netherlands (2018), Spain and Australia (2019).…”

Section: Discussionmentioning

confidence: 99%

Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs

Htar

Jackson²,

Balmer

et al. 2020

BMC Public Health

View full text Add to dashboard Cite

Background Monovalent meningococcal C conjugate vaccine (MCCV) was introduced into the routine immunization program in many countries in Europe and worldwide following the emergence of meningococcal serogroup C (MenC) in the late 1990s. This systematic literature review summarizes the immediate and long-term impact and effectiveness of the different MCCV vaccination schedules and strategies employed. Methods We conducted a systematic literature search for peer-reviewed, scientific publications in the databases of MEDLINE (via PubMed), LILACS, and SCIELO. We included studies from countries where MCCV have been introduced in routine vaccination programs and studies providing the impact and effectiveness of MCCV published between 1st January 2001 and 31st October 2017. Results Forty studies were included in the review; 30 studies reporting impact and 17 reporting effectiveness covering 9 countries (UK, Spain, Italy, Canada, Brazil, Australia, Belgium, Germany and the Netherlands). Following MCCV introduction, significant and immediate reduction of MenC incidence was consistently observed in vaccine eligible ages in all countries with high vaccine uptake. The reduction in non-vaccine eligible ages (especially population > 65 years) through herd protection was generally observed 3–4 years following introduction. Vaccine effectiveness (VE) was mostly assessed through screening methods and ranged from 38 to 100%. The VE was generally highest during the first year after vaccination and waned over time. The VE was better maintained in countries employing catch-up campaigns in older children and adolescents, compared to routine infant only schedules. Conclusions MCCV were highly effective, showing a substantial and sustained decrease in MenC invasive meningococcal disease. The epidemiology of meningococcal disease is in constant transition, and some vaccination programs now include adolescents and higher valent vaccines due to the recent increase in cases caused by serogroups not covered by MCCV. Continuous monitoring of meningococcal disease is essential to understand disease evolution in the setting of different vaccination programs.

show abstract

“…30 Following large pertussis epidemics and infant deaths, the US were the first to recommend maternal pertussis vaccination in 2011, 31 followed by several others. [32][33][34][35][36][37][38][39][40] In the United Kingdom (UK), US and Spain impact evaluations have shown an efficacy of 90% in reducing laboratory-confirmed pertussis, hospitalisations, and deaths in infants. [41][42][43][44][45][46][47] RSV is the most common cause of acute lower respiratory tract infection in children under five years of age globally, and is estimated to cause more than 30 million infections and nearly 60 000 in-hospital deaths in this age group annually.…”

Section: Pathogen Specific Overviewmentioning

confidence: 99%

Key considerations for successful implementation of maternal immunization programs in low and middle income countries

Krishnaswamy

Lambach

Giles

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The Maternal Neonatal Tetanus Elimination program is proof of concept for the feasibility and potential for maternal immunization to reduce neonatal mortality particularly in low and middle-income countries. Introduction of any additional vaccine into the antenatal space, such as Influenza and Pertussis, and potentially Respiratory Syncytial Virus and Group B Streptococcus vaccines in the future, requires strengthening of antenatal care and immunization services. Successful implementation also requires robust disease surveillance in pregnant women and neonates and active surveillance for adverse events following immunization to monitor the impact and ensure the safe use of the vaccine. This review outlines five key elements essential for successful implementation of a maternal immunization program focusing particularly on low and middle-income countries. These include; relevant considerations in supporting a decision to undertake a maternal immunization program including knowledge of local disease epidemiology, involvement of the consumer, healthcare provider recommendation, equitable access to maternal vaccination, and systems for disease surveillance, program evaluation and safety monitoring.

show abstract

Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations

Cited by 7 publications

References 24 publications

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs

Key considerations for successful implementation of maternal immunization programs in low and middle income countries

Contact Info

Product

Resources

About